XR 5118
Latest Information Update: 29 Jul 2004
Price :
$50 *
At a glance
- Originator Xenova Group
- Class Antithrombotics; Piperazines
- Mechanism of Action Plasminogen activator inhibitor-1 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Ischaemic heart disorders; Thrombosis
Most Recent Events
- 29 Jul 2004 Discontinued - Preclinical for Ischaemic heart disorders in Netherlands (unspecified route)
- 29 Jul 2004 Discontinued - Preclinical for Thrombosis in Netherlands (unspecified route)
- 25 Jul 2002 No development reported - Preclinical for Ischaemic heart disorders in Netherlands (unspecified route)